- The FDA approves Celgene's (NASDAQ:CELG -0.8%) Otezla (apremilast) for the treatment of adult patients with oral ulcers associated Behçet’s Disease, a rare inflammatory disorder that affects ~1 in 20,000 Americans.
- Otezla has been commercially available in the U.S. since 2014 for patients with plaque psoriasis and psoriatic arthritis.